Response Genetics, Inc. Announces Appointment of James Wynne as Vice President, Sales & Marketing
10/2/2012 10:22:56 AM
LOS ANGELES, Oct. 1, 2012 /PRNewswire/ -- Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and commercialization of molecular diagnostic tests for cancer, announced today the addition of James Wynne as the company's Vice President, Sales & Marketing. In this newly created position, Mr. Wynne will be responsible for leading the company's ResponseDX strategic and operational sales and marketing activities including the expansion of the company's direct sales efforts and identifying new service offerings.
"With Jim's strong background in providing results driven and advanced skills in sales management, marketing and communications in the clinical laboratory diagnostics space, we believe he is ideally suited to lead our ResponseDX sales and marketing efforts," said Thomas A. Bologna, Chairman & Chief Executive Officer of Response Genetics. "Jim's track record of building a performance driven sales team along with his true appreciation for how to market clinical testing services to pathologists and oncologists will be a tremendous asset to us. We are looking forward to his contributions."
Mr. Wynne has spent the last 20 plus years in cancer diagnostics. He spent the first six years in pharmaceutical sales moving into leadership roles. He joined Impath in 1995 as a Territory Sales Manager before being promoted to Director of Sales for the western region. Under his leadership revenue grew exponentially. After nine successful years, Mr. Wynne was recruited to UCLA Medical Center as the Director of Sales for UCLA's pathology outreach program. Mr. Wynne joins Response Genetics from Clarient, Inc. where he started in 2004 when the company was known as Chromavision Medical Systems. Mr. Wynne recruited and developed the original Clarient sales team and worked with the marketing group to prioritize product development. During his tenure, he directly helped the sales team grow to an approximately $115 million revenue generating organization at the time of its acquisition by GE Healthcare. Mr. Wynne received a BA in Sociology from the University of California, Los Angeles and an MBA from Pepperdine University.
Mr. Wynne, commenting on his appointment, "I am extremely excited about joining Response Genetics for a number of reasons. It's a perfect fit for my background, interests and skills, and I am happy to be a part of the leadership team that Tom has assembled to transition Response Genetics into a top line, sales driven, high growth company."
About Response Genetics, Inc.
Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit www.responsegenetics.com.
Forward-Looking Statement Notice
Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, or to successfully file a registration statement with the Securities Exchange Commission ("SEC"), and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.
These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the SEC. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.
Investor Relations Contact:
Thomas A. Bologna
Response Genetics, Inc.
SOURCE Response Genetics, Inc.